IL270749A - A new use of a formyl peptide receptor 2/lipoxin A4 receptor (FPR2/ALX) agonist for the treatment of heart failure - Google Patents
A new use of a formyl peptide receptor 2/lipoxin A4 receptor (FPR2/ALX) agonist for the treatment of heart failureInfo
- Publication number
- IL270749A IL270749A IL270749A IL27074919A IL270749A IL 270749 A IL270749 A IL 270749A IL 270749 A IL270749 A IL 270749A IL 27074919 A IL27074919 A IL 27074919A IL 270749 A IL270749 A IL 270749A
- Authority
- IL
- Israel
- Prior art keywords
- receptor
- fpr2
- lipoxin
- alx
- agonist
- Prior art date
Links
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 title 2
- 101150103751 FPR2 gene Proteins 0.000 title 1
- 101710109169 Formyl peptide receptor 2 Proteins 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 title 1
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 title 1
- 101000931587 Mus musculus Formyl peptide receptor-related sequence 1 Proteins 0.000 title 1
- 101100446655 Rhizopus delemar (strain RA 99-880 / ATCC MYA-4621 / FGSC 9543 / NRRL 43880) FKBP2 gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762509489P | 2017-05-22 | 2017-05-22 | |
| PCT/US2018/033783 WO2018217684A1 (en) | 2017-05-22 | 2018-05-22 | Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL270749A true IL270749A (en) | 2020-01-30 |
Family
ID=62567841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL270749A IL270749A (en) | 2017-05-22 | 2019-11-18 | A new use of a formyl peptide receptor 2/lipoxin A4 receptor (FPR2/ALX) agonist for the treatment of heart failure |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200069644A1 (enExample) |
| EP (1) | EP3630097A1 (enExample) |
| JP (1) | JP2020520948A (enExample) |
| KR (1) | KR20200006595A (enExample) |
| CN (1) | CN110662538A (enExample) |
| AU (1) | AU2018273382A1 (enExample) |
| BR (1) | BR112019024185A2 (enExample) |
| CA (1) | CA3064291A1 (enExample) |
| CL (1) | CL2019003325A1 (enExample) |
| CO (1) | CO2019013015A2 (enExample) |
| EA (1) | EA201992704A1 (enExample) |
| IL (1) | IL270749A (enExample) |
| MX (1) | MX2019013926A (enExample) |
| PE (1) | PE20200402A1 (enExample) |
| WO (1) | WO2018217684A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2869129T3 (es) * | 2017-06-09 | 2021-10-25 | Bristol Myers Squibb Co | Agonistas de piperidinona del receptor 2 de péptidos formilados |
| JP7700210B2 (ja) | 2020-07-09 | 2025-06-30 | ブリストル－マイヤーズ スクイブ カンパニー | ピラゾロンホルミルペプチド２受容体アゴニスト |
| JP7802765B2 (ja) | 2020-08-12 | 2026-01-20 | ブリストル－マイヤーズ スクイブ カンパニー | オキソピロリジン尿素ｆｐｒ２アゴニスト |
| KR20230084530A (ko) * | 2020-10-09 | 2023-06-13 | 브리스톨-마이어스 스큅 컴퍼니 | 아미노이미다졸 fpr2 효능제 |
| CN119055775A (zh) * | 2022-07-30 | 2024-12-03 | 中国医学科学院阜外医院 | Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途 |
| CN118831080B (zh) * | 2024-09-24 | 2024-11-22 | 上海交通大学医学院附属仁济医院 | 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1492552A2 (en) * | 2002-04-03 | 2005-01-05 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| NZ752095A (en) | 2013-11-28 | 2022-07-01 | Kyorin Seiyaku Kk | Urea derivative or pharmacologically acceptable salt thereof |
| KR101645015B1 (ko) * | 2014-03-11 | 2016-08-03 | 포항공과대학교 산학협력단 | Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물 |
-
2018
- 2018-05-22 MX MX2019013926A patent/MX2019013926A/es unknown
- 2018-05-22 EP EP18730584.2A patent/EP3630097A1/en not_active Withdrawn
- 2018-05-22 WO PCT/US2018/033783 patent/WO2018217684A1/en not_active Ceased
- 2018-05-22 AU AU2018273382A patent/AU2018273382A1/en not_active Abandoned
- 2018-05-22 JP JP2019564446A patent/JP2020520948A/ja active Pending
- 2018-05-22 CN CN201880033663.XA patent/CN110662538A/zh active Pending
- 2018-05-22 PE PE2019002437A patent/PE20200402A1/es unknown
- 2018-05-22 US US16/612,438 patent/US20200069644A1/en not_active Abandoned
- 2018-05-22 BR BR112019024185-0A patent/BR112019024185A2/pt not_active Application Discontinuation
- 2018-05-22 CA CA3064291A patent/CA3064291A1/en active Pending
- 2018-05-22 KR KR1020197037388A patent/KR20200006595A/ko not_active Withdrawn
- 2018-05-22 EA EA201992704A patent/EA201992704A1/ru unknown
-
2019
- 2019-11-18 IL IL270749A patent/IL270749A/en unknown
- 2019-11-20 CL CL2019003325A patent/CL2019003325A1/es unknown
- 2019-11-21 CO CONC2019/0013015A patent/CO2019013015A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018217684A1 (en) | 2018-11-29 |
| AU2018273382A1 (en) | 2020-01-16 |
| US20200069644A1 (en) | 2020-03-05 |
| CL2019003325A1 (es) | 2020-04-17 |
| PE20200402A1 (es) | 2020-02-26 |
| CN110662538A (zh) | 2020-01-07 |
| CO2019013015A2 (es) | 2020-01-17 |
| CA3064291A1 (en) | 2018-11-29 |
| EP3630097A1 (en) | 2020-04-08 |
| EA201992704A1 (ru) | 2020-03-19 |
| BR112019024185A2 (pt) | 2020-06-02 |
| MX2019013926A (es) | 2020-01-20 |
| KR20200006595A (ko) | 2020-01-20 |
| JP2020520948A (ja) | 2020-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3989972T3 (pl) | Agoniści receptora glukagonopodobnego peptydu 1 | |
| ZA202006115B (en) | Phenylpyrrolidinone formyl peptide 2 receptor agonists | |
| IL267660A (en) | Method for treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to gastric inhibitory peptide receptor antagonists | |
| IL259468A (en) | The reference to formyl peptide receptor 2/lipoxin receptor 4a (fpr2/alx) for the treatment of heart disease | |
| IL261846A (en) | A method for cleaning glucagon-like peptide analogues | |
| IL273253A (en) | Glucagon-like peptide-1 receptor agonists and their uses | |
| CA3263567A1 (en) | Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins | |
| SG11201912195TA (en) | Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies | |
| MX2019013926A (es) | Uso novedoso de un agonista del receptor 2 de formil peptido/receptor a4 de lipoxina (fpr2/alx) para el tratamiento de insuficiencia cardiaca. | |
| IL290137A (en) | Application of a polypeptide or derivative thereof | |
| IL270199A (en) | Peptides for the treatment of diabetes | |
| ZA202006157B (en) | Pharmaceutical composition of kor receptor agonist | |
| HUE069752T2 (hu) | Adaptív Compton kamera orvosi képalkotáshoz | |
| HUE062092T2 (hu) | Neuropátiás fájdalom kezelésére szolgáló, alacsony koncentrációjú FLT-receptorgátló | |
| EP3549948A4 (en) | AGONISTIC PEPTIDE FOR ADIPONECTIN RECEPTOR | |
| HK40022853A (en) | Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure | |
| IL284029B1 (en) | Peptides for the treatment and prevention of diabetes and related disorders | |
| HUE064558T2 (hu) | Fájdalom kezelése 3-as szerotoninreceptor agonistájával | |
| HK40023936A (en) | Glucagon-like peptide 1 receptor agonists and uses thereof | |
| HK40002410A (en) | Inhibitors of beta-arrestin-neurokinin 1 receptor interactions for the treatment of pain | |
| AU2016900635A0 (en) | Inhibitors of beta-arrestin-Neurokinin 1 Receptor Interactions for the Treatment of Pain |